Journal of Molecular Neuroscience

, Volume 18, Issue 1–2, pp 7–14

Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier

  • Abba J. Kastin
  • Victoria Akerstrom
  • Weihong Pan
Peptide Drug Design, Pharmacology, And Delivery In Health And Disease

Abstract

Glucagon-like peptide-1 (GLP-1) reduces insulin requirement in diabetes mellitus and promotes satiety. GLP-1 in the periphery (outside the CNS) has been shown to act on the brain to reduce food ingestion. As GLP-1 is readily degraded in blood, we focused on the interactions of [Ser8]GLP-1, an analog with similar biological effects and greater stability, with the blood-brain barrier (BBB). The influx of radiolabeled [Ser8]GLP-1 into brain has several distinctive characteristics:
  1. 1.

    A rapid influx rate of 8.867±0.798 × 104 mL/g-min as measured by multiple-time regression analysis after iv injection in mice.

     
  2. 2.

    Lack of self-inhibition by excess doses of the unlabeled [Ser8]GLP-1 either iv or by in situ brain perfusion, indicating the absence of a saturable transport system at the BBB.

     
  3. 3.

    Lack of modulation by short-term fasting and some other ingestive peptides that may interact with GLP-1, including leptin, glucagon, insulin, neuropeptide Y, and melanin-concentrating hormone.

     
  4. 4.

    No inhibition of influx by the selective GLP-1 receptor antagonist exendin(9–39), suggesting that the GLP-1 receptor is not involved in the rapid entry into brain.

     

Similarly, there was no efflux system for [Ser8]GLP-1 to exit the brain other than following the reabsorption of cerebrospinal fluid (CSF). The fast influx was not associated with high lipid solubility. Upon reaching the brain compartment, substantial amounts of [Ser8]GLP-1 entered the brain parenchyma, but a large proportion was loosely associated with the vasculature at the BBB. Finally, the influx rate of [Ser8]GLP-1 was compared with that of GLP-1 in a blood-free brain perfusion system; radiolabeled GLP-1 had a more rapid influx than its analog and neither peptide showed the self-inhibition indicative of a saturable transport system. Therefore, we conclude that [Ser8]GLP-1 and the endogenous peptide GLP-1 can gain access to the brain from the periphery by simple diffusion and thus contribute to the regulation of feeding.

Index Entries

Feeding blood-brain barrier GLP-1 peptide 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Banks W. A., Fasold M. B., and Kastin A. J. (1997) Measurement of efflux rates from brain to blood, in Methods of Molecular Biology, Neuropeptide Protocols, Vol. 73 (Irvine G. B. and Williams C. H., eds.), Humana Press Inc., Totowa, NJ, pp. 353–360.Google Scholar
  2. Banks W. A. and Kastin A. J. (1989) Quantifying carrier-mediated transport of peptides from the brain to the blood, in Methods in Enzymology, Vol. 168, Conn, P. M. (ed.), Academic Press, San Diego, pp. 652–660.Google Scholar
  3. Creutzeldt W. O. C., Kleine N., Willms B., Orskov C., Holst J. J., and Nauck M. A. (1996) Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7–36) amide type 1 diabetic patients. Diabetes Care 19, 580–586.CrossRefGoogle Scholar
  4. Dauch P., Masuo Y., Vincent J. P., and Checler F. (1993) A survey of the cerebral regionalization and ontogeny of eight exo- and endopeptidases in murines. Peptides 14, 593–599.PubMedCrossRefGoogle Scholar
  5. Elias C. F., Kelly J. F., Lee C. E., et al. (2000) Chemical characterization of leptin-activated neurons in the rat brain. J. Comp. Neurol. 423, 261–281.PubMedCrossRefGoogle Scholar
  6. Flint A., Raben A., Astrup A., and Holst J. J. (1998) Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J. Clin. Invest. 101, 515–520.PubMedCrossRefGoogle Scholar
  7. Goldstone A. P., Mercer J. G., Gunn I., et al. (1997) Leptin interacts with glucagon-like peptide-1 neurons to reduce food intake and body weight in rodents. FEBS Lett. 415, 134–138.PubMedCrossRefGoogle Scholar
  8. Gutzwiller J.-P., Drewe J., Goke B., et al. (1999) Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am. J. Physiol. 276, R1541-R1544.PubMedGoogle Scholar
  9. Hansen L., Deacon C. F., Orskov C., and Holst J. J. (1999) Glucagon-like peptide-1-(7–36)amide is transformed to glucagon-like peptide-1-(9–36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 140, 5356–5363.PubMedCrossRefGoogle Scholar
  10. Jin S. L., Han V. K., Simmons J. G., Towle A. C., Lauder J. M., and Lund P. K. (1988) Distribution of glucagon-like peptide I (GLP-I), glucagon, and glicentin in the rat brain: an immunocytochemical study. J. Comp. Neurol. 271, 519–532.PubMedCrossRefGoogle Scholar
  11. Kanse S. M., Kreymann B., Ghatei M. A., and Bloom S. R. (1988) Identification and characterization of glucagon-like peptide-1 7–36 amide-binding sites in the rat brain and lung. FEBS Lett. 241, 209–212.PubMedCrossRefGoogle Scholar
  12. Kastin A. J. and Akerstrom V. (1999a) Nonsaturable entry of neuropeptide Y into the brain. Am. J. Physiol. 276, E479-E482.PubMedGoogle Scholar
  13. Kastin A. J. and Akerstrom V. (1999b) Orexin A but not orexin B rapidly enters brain from blood by simple diffusion. J. Pharmacol. Exp. Ther. 289, 219–223.PubMedGoogle Scholar
  14. Kastin A. J., Akerstrom V., Hackler L., and Zadina J. E. (2000) Phe13,Tyr19-Melanin-concentrating hormone and the blood-brain barrier: role of protein binding. J. Neurochem. 74, 385–391.PubMedCrossRefGoogle Scholar
  15. Kastin A. J. and Akerstrom V. (1999) Entry of CART into brain is rapid but not inhibited by excess CART or leptin. Am. J. Physiol. 277, E901-E904.PubMedGoogle Scholar
  16. Kastin A. J., Akerstrom V., and Hackler L. (2000) Agouti-related protein (83–132) aggregates and crosses the blood-brain barrier slowly. Metabolism 49, 1444–1448.PubMedCrossRefGoogle Scholar
  17. Kastin A. J., Hahn K., and Zadina J. E. (2001) Regional differences in peptide degradation by rat cerebral microvessels: a novel regulatory mechanism for communication between blood and brain. Life Sci. 69, 1305–1312.PubMedCrossRefGoogle Scholar
  18. Kieffer T. J., McIntosh C. H. S., and Pederson R. A. (1995) Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136, 3585–3596.PubMedCrossRefGoogle Scholar
  19. Kreymann B., Ghatei M. A., Burnet P., et al. (1989) Characterization of glucagon-like peptide-1-(7–36) amide in the hypothalamus. Brain Res. 502, 325–331.PubMedCrossRefGoogle Scholar
  20. Larsen P. J., Tang-Christensen M., Holst J. J., and Orskov C. (1997) Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 77, 259–270.CrossRefGoogle Scholar
  21. Mercer J. G., Moar K. M., Findlay P. A., Hoggard N., and Adam C. L. (1998) Association of leptin receptor (OB-Rb), NPY and GLP-1 gene expression in the ovine and murine brainstem. Regul. Pept. 75–76, 271–278.PubMedCrossRefGoogle Scholar
  22. Naslund E., Barkeling B., King N., et al. (1999) Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int. J. Obesity 23, 304–311.CrossRefGoogle Scholar
  23. Ritzel U., Leonhardt U., Ottleben M., et al. (1998) A synthetic glucagon-like peptide-1 analog with improved plasma stability. J. Endocrinol. 159, 93–102.PubMedCrossRefGoogle Scholar
  24. Shimizu I., Hirota M., Ohboshi C., and Shima K. (1987) Identification and localization of glucagon-like peptide-1 and its receptor in rat brain. Endocrinology 121, 1076–1082.PubMedCrossRefGoogle Scholar
  25. Tang-Christensen M., Larsen P. J., Goke R., et al. (1996) Central administration of GLP-1-(7–36) amide inhibits food and water intake in rats. Am. J. Physiol. 271, R848-R856.PubMedGoogle Scholar
  26. Toft-Nielsen M. B., Madsbad S., and Holst J. J. (1999) Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22, 1137–1143.PubMedCrossRefGoogle Scholar
  27. Tritos N. A., Vincent D., Gillette J., Ludwig D. S., Flier E. S., and Maratos-Flier E. (1998) Functional interactions between melanin-concentrating hormone, neuropeptide Y, and anorectic neuropeptides in the rat hypothalamus. Diabetes 47, 1687–1692.PubMedCrossRefGoogle Scholar
  28. Turton M. D., O’Shea D., Gunn I., et al. (1996) A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379, 69–72.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2002

Authors and Affiliations

  • Abba J. Kastin
    • 1
  • Victoria Akerstrom
    • 1
  • Weihong Pan
    • 1
  1. 1.VA Medical Center and Tulane University School of MedicineNew Orleans

Personalised recommendations